A Pilot Trial to Evaluate the Effects of Dextromethorphan in Patients Suffering From Cancer-Related Fatigue
OBJECTIVES:
Primary
- Assess the effects of dextromethorphan hydrobromide in patients with cancer-related
fatigue.
Secondary
- Correlate the changes in cancer-related fatigue with the levels of plasma homocysteine
versus red blood cell folate.
OUTLINE: This is a multicenter, open-label, pilot study.
Patients receive oral dextromethorphan hydrobromide 3 times a day on days 1-7. Treatment
repeats weekly for up to 3 weeks in the absence of disease progression or unacceptable
toxicity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Interventional
Masking: Open Label, Primary Purpose: Supportive Care
Efficacy
Susan Goodin, PharmD, FCCP, BCOP
Principal Investigator
Cancer Institute of New Jersey
United States: Federal Government
CDR0000539650
NCT00176540
October 2003
August 2007
Name | Location |
---|---|
Cancer Institute of New Jersey at Hamilton | Hamilton, New Jersey 08690 |
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick, New Jersey 08903 |